

Indivior Publications 2019

Manuscripts

Treatment of Opioid Use Disorder

1. Ling W, Nadipelli V, Ronquest N, Albright V, Aldridge A, Learned S, Mehra V, Heidbreder C. Remission from Chronic Opioid Use—Studying Environmental and Socio-economic Factors on Recovery (RECOVER): study design and participant characteristics. *Contemp Clin Trials*. 2019;76: 93-103. <https://doi.org/10.1016/j.cct.2018.11.015>
2. Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet*. 2019;393(10173):778-790. [https://doi.org/10.1016/S0140-6736\(18\)32259-1](https://doi.org/10.1016/S0140-6736(18)32259-1)
3. Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh Y-C, Learned SM, Mehra V, Heidbreder C. Patient-Centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study. *J Addiction Med*, Epub 2019 Mar 4. <https://doi.org/10.1097/ADM.0000000000000517>
4. Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young, MA (2019) Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. *Clin Pharmacol Ther*, Epub 2019 Feb 22. <https://doi.org/10.1002/cpt.1406>

Abstracts

Treatment of Opioid Use Disorder

1. Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase 3 study. *Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting*. San Diego, CA; March 25-28, 2019.
2. Andorn A, Haight B, Greenwald MK, Zhao S, Fox NL, Heidbreder C, Learned SM. Higher abstinence rates with greater buprenorphine exposure among patients who inject opioids. *Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting*. San Diego, CA; March 25-28, 2019.
3. Ling W, Nadipelli VR, Ronquest N, Aldridge CT, Solem N, Peiper S, Learned SM, Heidbreder C. Recovery from OUD following monthly extended-release buprenorphine treatment: 12-month longitudinal outcomes. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.
4. Wiest K, van Velzen M, Algra H, Moss L, Dobbins R. High therapeutic buprenorphine levels reduce IV fentanyl respiratory depression. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.
5. Andorn A, Boyett B, Shinde S, Fox NL, Zhao Y, Learned SM. Long-term RBP-6000, sustained-release buprenorphine for moderate-to-severe OUD. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.
6. Wiest K, Andorn A, Fox NL, Learned S, Zhao Y, Gray F. Abstinence response to 300mg vs 100mg RBP-6000 among opioid injection users. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.

Treatment of Schizophrenia

1. Thompson S, Andorn A, Nadipelli VR, Graham J, De Veugh-Geiss A, Learned SM, Heidbreder C. The budget impact of PERSERIS™: a once-monthly long-acting injectable (LAI) antipsychotic in patients with schizophrenia. Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting. San Diego, CA; March 25-28, 2019.
2. Thompson S, Andorn A, Nadipelli VR, Graham J, De Veugh-Geiss A, Learned SM, Heidbreder C. The cost-effectiveness of PERSERIS™: a once-monthly long-acting injectable antipsychotic in patients with schizophrenia. Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting. San Diego, CA; March 25-28, 2019.